Bio-Rad Laboratories (BIO) Expected to Announce Quarterly Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) is expected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $2.57 per share and revenue of $694.6380 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Bio-Rad Laboratories Stock Up 1.6%

NYSE:BIO opened at $299.75 on Wednesday. The company has a current ratio of 5.44, a quick ratio of 3.94 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average of $307.77 and a 200-day moving average of $300.91. The firm has a market capitalization of $8.09 billion, a PE ratio of -12.33 and a beta of 1.18. Bio-Rad Laboratories has a 52 week low of $211.43 and a 52 week high of $343.12.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Citigroup increased their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company increased their price objective on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and an average price target of $358.50.

Institutional Trading of Bio-Rad Laboratories

A number of institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Bio-Rad Laboratories by 2,271.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock valued at $111,363,000 after acquiring an additional 380,422 shares during the period. Scopia Capital Management LP bought a new position in Bio-Rad Laboratories during the 2nd quarter valued at $22,862,000. Man Group plc increased its position in shares of Bio-Rad Laboratories by 1,096.0% during the 2nd quarter. Man Group plc now owns 80,288 shares of the medical research company’s stock valued at $19,375,000 after purchasing an additional 73,575 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth $15,347,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Bio-Rad Laboratories by 45.6% in the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after buying an additional 32,874 shares during the period. 65.24% of the stock is owned by institutional investors and hedge funds.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.